

Supplementary:

```

AZ6080      1 mfakivavsltltasgqlaaeckvtvdstdqmsfdtkaeidkscskft      50
BSEQ0021295 1 MLRKLAAVSLLSLLSAPLLAAECSVDIQGNDQMCFNTNAITVDKSCSKQFT  50

AZ6080      51 vdlkhsnglpknvmghnvwltteadmqqvategmaagidknylkegdtri    100
BSEQ0021295 51 VNLSPGNLFPKNVMGHNVWLSTAADMQGVVTDGMASGLDKDYLPDSDSRV  100

AZ6080      101 iahtkiigagetdsvtfdvsklkadgkymffcsfpghismmkgvtlkl    148
BSEQ0021295 101 IAHTKLIIGSGEKDSVTFDVSCLKKEGEQYMFCTFPGHSAALMKGTLLK  148

```

Figure S1. Comparison of *Pseudomonas* sp TAE6080 and *Pseudomonas aeruginosa* PAO1 Azurin. Comparison of the amino acid sequences of *Pseudomonas* sp. TAE6080 Cold-Azurin (Az6080) and the Azurin produced by *Pseudomonas aeruginosa* PAO1 (BSEQ0021295).




Figure S2. Protein profile and anti-adhesive activity of periplasmic fraction from recombinant *E. Coli* BL21DE3. (A) SDS-PAGE 15% stained with Coomassie blue, protein profile of periplasmic fraction from recombinant *E. Coli* BL21DE3 induced (+ IPTG) or non-induced (-IPTG) cells. .M: molecular weight marker. (B) Biofilm formation by *S. epidermidis* O-47 in polystyrene 24-wells microtiter plate wells coated with periplasmic fraction from recombinant *E. Coli* BL21DE3 induced (+ IPTG) or non-induced (-IPTG) cells.




Figure S3. Antibiofilm activity of poxA1b laccase. Laccase (PoxA1b) antibiofilm activity against *S. epidermidis* O-47 (A) or *S. epidermidis* RP62A (B). Concentrations shown in the assay (0.25 mg/mL or 0.125 mg/mL) correspond to 3.75 U/mL or 1.87 U/mL of poxA1b used for the experiment. Each data point represents the mean \pm SD of four independent samples. The results are expressed as the percentage of biofilm formed in the

presence of laccase compared to untreated bacteria (100%). Biofilm formation was considered unaffected in the range of 90–100%.